Red Light Holland engages Kala Bio’s Researgency.ai platform for PEX010 clinical development support

Reuters03-18

Red Light Holland engages <a href="https://laohu8.com/S/KALA">Kala Bio</a>’s Researgency.ai platform for PEX010 clinical development support

Red Light Holland has engaged Kala Bio to use the Researgency.ai agentic AI platform to support the clinical development strategy for Filament Health’s patented botanical psilocybin drug candidate, PEX010. The platform will deploy AI research agents to assist with clinical planning, protocol optimization, and scenario modeling for PEX010. Red Light said it recently signed a definitive arrangement agreement to acquire Filament’s business, including 76 issued patents across 15 patent families and its lead drug candidate, PEX010.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Red Light Holland Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603180815NEWSFILECNPR____20260318_288957_1) on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620534432?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 20:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620534432","market":"nz","top_or_hot":-1,"title":"Red Light Holland engages Kala Bio’s Researgency.ai platform for PEX010 clinical development support","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Red Light Holland engages <a href=\"https://laohu8.com/S/KALA\">Kala Bio</a>’s Researgency.ai platform for PEX010 clinical development support\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Red Light Holland has engaged Kala Bio to use the Researgency.ai agentic AI platform to support the clinical development strategy for <a href=\"https://laohu8.com/S/FLHLF\">Filament Health</a>’s patented botanical psilocybin drug candidate, PEX010. The platform will deploy AI research agents to assist with clinical planning, protocol optimization, and scenario modeling for PEX010. Red Light said it recently signed a definitive arrangement agreement to acquire Filament’s business, including 76 issued patents across 15 patent families and its lead drug candidate, PEX010.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/TRUFF\">Red Light Holland Corp.</a> published the original content used to generate this news brief via Newsfile (Ref. ID: 202603180815NEWSFILECNPR____20260318_288957_1) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Red Light Holland engages Kala Bio’s Researgency.ai platform for PEX010 clinical development support</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRed Light Holland engages Kala Bio’s Researgency.ai platform for PEX010 clinical development support\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 20:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Red Light Holland engages <a href=\"https://laohu8.com/S/KALA\">Kala Bio</a>’s Researgency.ai platform for PEX010 clinical development support\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Red Light Holland has engaged Kala Bio to use the Researgency.ai agentic AI platform to support the clinical development strategy for <a href=\"https://laohu8.com/S/FLHLF\">Filament Health</a>’s patented botanical psilocybin drug candidate, PEX010. The platform will deploy AI research agents to assist with clinical planning, protocol optimization, and scenario modeling for PEX010. Red Light said it recently signed a definitive arrangement agreement to acquire Filament’s business, including 76 issued patents across 15 patent families and its lead drug candidate, PEX010.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/TRUFF\">Red Light Holland Corp.</a> published the original content used to generate this news brief via Newsfile (Ref. ID: 202603180815NEWSFILECNPR____20260318_288957_1) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KALA","symbol_name":"KALA BIO","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6vZBh0:1","article_id":"2620534432","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620534432","pubTimestamp":1773836208,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Red Light Holland has engaged Kala Bio to use the Researgency.ai agentic AI platform to support the clinical development strategy for Filament Health’s patented botanical psilocybin drug candidate, PEX010. The platform will deploy AI research agents to assist with clinical planning, protocol optimization, and scenario modeling for PEX010. Red Light said it recently signed a definitive arrangement agreement to acquire Filament’s business, including 76 issued patents across 15 patent families and its lead drug candidate, PEX010.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KALA":"KALA BIO","BK4139":"生物科技","BK4007":"制药","FLHLF":"Filament Health Corp."},"translate_title":"Red Light Holland聘请Kala Bio的Researgency.ai平台提供PEX010临床开发支持","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KALA":0.9,"FLHLF":0.9},"content_text":"Red Light Holland engages Kala Bio’s Researgency.ai platform for PEX010 clinical development support\n    \n\n        Red Light Holland has engaged Kala Bio to use the Researgency.ai agentic AI platform to support the clinical development strategy for Filament Health’s patented botanical psilocybin drug candidate, PEX010. The platform will deploy AI research agents to assist with clinical planning, protocol optimization, and scenario modeling for PEX010. Red Light said it recently signed a definitive arrangement agreement to acquire Filament’s business, including 76 issued patents across 15 patent families and its lead drug candidate, PEX010.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Red Light Holland Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603180815NEWSFILECNPR____20260318_288957_1) on March 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620534432","isCrawlerRequest":true}